Procter & Gamble (PG) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Procter & Gamble (PG)

147.41

+0.44 (0.30%)

as of Jul 24, 2026, 8:00:00 pm Market Open.

240 watching

Investor Insights

Jul 26, 2026, 12:00 am

This summary was created by AI, based on 11 opinions in the last 12 months.

Procter & Gamble (PG) has seen a challenging environment with significant concerns regarding the consumer staples sector. Several experts indicate that the company is experiencing difficulties, notably a decline in earnings growth and rising input costs. However, PG remains a dividend aristocrat, offering a near 3% dividend yield, which makes it appealing for some investors. Despite the gloomy outlook, there is a belief that PG may provide a defensive stance during economic downturns, with thoughts that its excellent brand portfolio can lead to a potential bounce back. A few experts suggest that entering the stock gradually might be wise, considering the current pricing and its valuation metrics reflecting a relatively low price-to-earnings ratio, even as overall consumer demand appears weak.

Consensus

Neutral

Valuation

Undervalued

Similar

Nestle, NESN

BUY

PG vs. UL Canadians can't ignore the Chinese and Indian markets. They do have political risk, but they will be delivering meaningful prosperity, so ignore that at your peril. PG had a very tough time after the global financial crisis. Still a great company and continues to do well, has outperformed UL. UL is going through changes, and these could lead to outperformance over PG. If you want safe and steady bond proxies, these are the types of companies you want to be thinking about.

BUY

They report Tuesday. Shares have been rallying since reporting organic growth that their peers lack. That said, he prefers JNJ.

DON'T BUY

PG vs. JNJ JNJ valuation of 16-17x earnings is cheaper than PG. JNJ has 3 areas: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. JNJ's medical device side should do well post-Covid. Dividends similar in the 2.5% range.

PARTIAL BUY

A solid buy that you buy over time, a piece at a time, and reinvest the dividends.

DON'T BUY

They report Tuesday. They face tough comps vs. the stay-at-home numbers, and too much competition to pass higher costs to consumers.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly PG is a global leader in consumer staples with brands recognized in over 180 countries. Recent earnings showed a 200% increase in EPS and is expected to grow over 9% over the next five years -- a real steady Eddy. It pays a nice dividend, backed by a 57% payout ratio. We would buy this with a stop loss at $100, looking to achieve $152 -- upside potential over 14%. Yield 2.38% (Analysts’ price target is $151.44)

COMMENT

Reports Wednesday. For once, their numbers will be boosted by a strong US dollar, not pressured by a weak one. They move a ton of merchandise overseas.

BUY

There's a bull market in hygiene, given Covid. The PG CFO expects such clean habits to continue after the pandemic--hygiene won't go away. Consumer habits die hard.

HOLD

This sector has held up reasonably well during this downturn along with utilities. She would continue to hold it and likes the dividend it pays.

COMMENT

He owns Unilever for their global exposure. P&G beat earnings but their revenues were down. It's trading like a growth stock even though it isn't. They have been coming out with new products. There is progress in grooming products but their baby care has been struggling. He also doesn't like their compliance and ethics. They reward 10% of their float to their executives and not helping employees. They are also make polluting products like Pampers and Swiffers.

SELL

The stock, but also the PE has taken off after doing nothing for years. Good observation of the PE as well as stock price. PG are getting rid of their shaving business, which is a debacle with a huge write-down. Exit this, because what you expected to happen to this stock has already happened.

DON'T BUY

They keep innovating unlike peers like Kraft. Doesn't know the valuation, but it's a fine company. This will do well. But he'd rather buy Google, Facebook or Apple for more growth. PG will barely grow.

PARTIAL SELL

They had a huge run in the last 18 months but it lagged the group for 4-5 years prior to that. It was because their products we selling to the higher end market. He is always in favour of re-weighting a stock when it has had a run-up.

COMMENT

You're paying a rich price now. It's had a straight run-up since early-2018, but has been sideways for the last quarter. It may do well for the next 18 months, but likely not as well as the past 18 months.

DON'T BUY

One of the headwinds is the trend toward generic products. Consumers aren't as interested in name brands. Only 3-5% growth of revenues and earnings. For a 25x multiple company, that's just not good enough. Investors have pushed the price up to extreme valuations for what the fundamentals support.

Showing 61 to 75 of 234 entries

Most Recent Experts

Andrew Pink

LDIC

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Procter & Gamble (PG)